Current partnerships

Xilio Therapeutics – In February, 2021 AskGene Pharma signed a patent cross-licensing agreement with Xilio Therapeutics of Waltham, Massachusetts for the development, production, and commercialization of cytokine-based products for oncology indications.  As part of the agreement, Xilio gained access to a part of AskGene’s cytokine prodrug IP. In return, AskGene receives the rights to develop, produce, and commercialize the products in the Asia Pacific region (except Japan).